Educational information

This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.

The objectives of the meeting were to:

• Review recent outcome data with PCSK9 inhibitors in the clinical management of patients who had a recent MI
• Discuss the importance of reaching LDL-c targets in patients post MI
• Provide a European expert perspective on the current challenges of reaching LDL-c targets and use of PCSK9 inhibitors in clinical cardiology
• Define key challenges, needs and goals for education to ensure the implications of new outcome trials like FOURIER and ODYSSEY-outcomes will be adopted in post MI patients
• Develop a consensus and clinical guidance on lowering LDL-c in post MI patients

Other topics covered in this series

Other lectures part of this educational series are:

• LDL-c as target in cardiology: The road towards lower targets - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Chris Packard, MD, Glasgow, Scotland, UK
• The guidelines in need of a major change? - Prof. Kausik Ray, MD, London, UK, & Prof. François Mach, MD, Geneva, Switzerland
• What are the key issues and challenges impacting clinical management with novel therapeutics? - Prof. Kausik Ray, MD, London, UK, & Prof. Gilles Montalescot, MD, Paris, France
• Progressive CAD despite low LDL-c an elusive disease - Prof. Kausik Ray, MD, London, UK, & Prof. Wouter Jukema, MD, Leiden, The Netherlands
• How are the guidelines for progressive CAD guiding us in clinical practice? - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Ulf Landmesser, MD, Berlin, Germany
• FH in clinical cardiology: highly prevalent. Challenges for screening and treatment of FH patients - Prof. Kausik Ray, MD, London, UK, & Prof. Kees Hovingh, MD, Amsterdam, The Netherlands

Faculty

Prof. John J.P Kastelein, internist, Amsterdam University Medical Centers, The Netherlands

Prof. Lluis Masana, internist, University Rovira and Virgili, Reus-Tarragona, Spain

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.